within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BX17_Carfloglitazar;
model Carfloglitazar 
   extends Pharmacolibrary.Drugs.ATC.A.A10BX17;

  annotation(Documentation(
    info ="<html><body><p>Carfloglitazar is a dual PPAR alpha and gamma agonist developed for the treatment of type 2 diabetes mellitus. It works by improving insulin sensitivity and modulating lipid metabolism. As of 2024, carfloglitazar is not an approved or marketed drug and was primarily investigated in early-phase clinical trials.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic studies are available for carfloglitazar in humans. The following parameters are estimated based on typical values for drugs in this class (PPAR agonists) and preclinical information.</p><h4>References</h4><ol></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Carfloglitazar;
